Targets › DMPK
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Jul 2028.
Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. (UniProt, Q09013)
Open in Phaseline: the race on DMPK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Dyne Therapeutics | zeleciment basivarsen (DYNE-101) antisense oligonucleotide targeting DMPK mRNA | DMPK | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | Jul 2028 |
Myotonic Dystrophy Type 1 (DM1) (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.